Firefly Neuroscience Inc（AIFF）股票分析AIFFFirefly Neuroscience Inc

Firefly Neuroscience, Inc. is an artificial intelligence (AI) company advancing precision neuroscience. The Company's BNA Platform and Evoke System are Class II medical devices, which were cleared by FDA for commercialization. The Company's FDA-510(k) cleared Evoke System, commercially deployed as the Evoke System, is in active use over 85 clinical sites in the United States. The Company has developed Firefly Platform, a vertically integrated hardware, software, and data infrastructure that captures standardized electroencephalographic (EEG) and event-related potential (ERP) assessments at the point of care, analyzes that data through its proprietary analytics engine, and delivers structured, clinician-ready reports back to the provider, all within a single seamless workflow. Its proprietary analytics engine analyzes raw EEG and ERP signals across captured dimensions and compares each patient’s electrophysiological profile to a reference dataset. It operates in the Technology sector.

Firefly Neuroscience Inc. (AIFF) is not a good buy right now due to its extremely low RSI of 22.098, indicating it is oversold, and a significant 20-day change of -54.25%. The stock has also shown a 1-year change of -54.70%, reflecting a long-term downtrend. While there are positive catalysts such as strategic partnerships with the Department of War and Radial, the financials show a concerning net income loss of -2,098,000 USD in Q2 2026, alongside a high price-to-sales ratio of 8.896, suggesting overvaluation. The main risk is the recent performance, with a 5-day change of -9.84%, indicating continued downward pressure on the stock price.